Sound
Health Research Institute
Institutional Review Board Guidelines
SHRI Home Page: www.soundhealthresearch.org
Credentials
Committee Main Page
The
Sound Health Research Institute (SHRI) Institutional Review Board (IRB) has the
responsibility to review, and the authority to approve or disapprove, all
research activities that use SHRI facilities, data, staff resources, or
funding. Moreover, they retain the same
responsibility to previously approved activities.
The
IRB is established to protect the rights and welfare of human research subjects
recruited to participate in Human BioAcoustics research activities.
The IRB reviews research proposals to assess the risks and benefits for the
human subjects to be studied. Each proposal is reviewed using criteria
described in Human BioAcoustics Research Protection of Human Subjects. The
research proposals are reviewed for safety, confidentiality (information about
individuals is not released to anyone), degree of benefit, and the need for and
quality of informed consent.
Human BioAcoustics Research Protection of Human Subjects
The SHRI IRB ensures that all research
observes three principles of ethics: (1) respect for persons; (2) beneficence
(to do no harm, and to maximize benefit); and, (3) justice. The IRB looks closely at the negotiation
between researcher and each potential volunteer, called the “informed consent
process.”
The following table shows how those
three ethical principles in research apply to individual volunteers.
Ethical
Principles |
Individual
Person |
Respect for Person and Respect for
Community |
·
People are autonomous; researchers
must give them required information and obtain their fully informed consent ·
The research does only what the
person consents to. For instance,
people are not identified in results without their explicit consent; they can
refuse or withdraw their participation without pressure ·
Special people have special
concerns. For instance, IRB should
include members with expertise about such concerns. |
Beneficence |
·
Maximize benefits to individual
volunteers. For instance, report
their findings to them. ·
Minimize risks to
individuals. For instance, protect
their privacy to avoid being stigmatized |
Justice |
·
People with less power should
not be asked to undergo risky research that is of little benefit to them ·
People with less power should
be included in potentially beneficial research |
IRB
Protocol Review Standards - Criteria for IRB approval of research
IRB members are responsible for overseeing:
The IRB review standards table contains suggested
questions that should be asked when considering if a research protocol meets
regulatory requirements.
IRB Review Standards
Table
Regulatory
review requirement |
Suggested
questions for IRB discussion |
1.
The proposed research design is scientifically sound & will not
unnecessarily expose subjects to risk. |
(a) Is
the hypothesis clear? Is it clearly stated? |
2.
Risks to subjects are reasonable in relation to anticipated benefits, if any, to
subjects, and the importance of knowledge that may reasonably be expected to
result. |
(a) What
does the IRB consider the level of risk to be? |
3.
Subject selection is equitable. |
(a) Who
is to be enrolled? Men? Women? Ethnic minorities?
Children (rationale for inclusion/exclusion addressed)? Seriously-ill
persons? Healthy volunteers? |
4.
Additional safeguards required for subjects likely to be vulnerable to
coercion or undue influence. |
(a) Are
appropriate protections in place for vulnerable subjects, e.g., pregnant
women, fetuses, socially- or economically-disadvantaged,
decisionally-impaired? |
5.
Informed consent is obtained from research subjects or their legally
authorized representative(s). |
(a) Does
the informed consent document include the required elements? |
6.
Subject safety is maximized. |
(a) Does
the research design minimize risks to subjects? |
7.
Subject privacy & confidentiality are maximized. |
(a) Will
personally-identifiable research data be protected to the extent possible
from access or use? |
The
IRB has the authority to approve, require modifications in, or disapprove all
research activities that fall within its jurisdiction as specified by both the
federal regulations and local institutional policy. If the IRB determines that
the research presents significant physical, social, or ethical risks to
subjects, the IRB may modify, suspend, or terminate approval research that has
been associated with serious harm to subjects.
IRB Membership
Membership shall:
consist of a diversity of members including consideration of race,
gender, cultural backgrounds and sensitivity to such issues as community
attitudes;
include at least one member with primary concerns in the scientific
area and at least one with primary concerns in the non-scientific area;
and include one member otherwise unaffiliated with the SHRI.
The potential for conflicts of interest should be considered when
selecting membership candidates.
Training
All
IRB members are required to complete a computer-based training (CBT) that
provides more detailed information about their roles and responsibilities. NIH
IRB on-line course:
http://ohsr.od.nih.gov/IRBCBT/intro.html
On-line course for researchers:
http://www.stanford.edu/dept/DoR/hs/
Functions
of the IRB
The
IRB will:
conduct
initial and continuing review of research and report its findings and actions
to the investigator and the institution;
determine
which projects require review more often than annually and which projects need
verification from sources other than the investigators that no material changes
have occurred since previous IRB review;
ensure
prompt reporting to the IRB of proposed changes in a research activity, and
ensure that such changes in approved research, during the period for which IRB
approval has already been given, may not be initiated without IRB review and
approval except when necessary to eliminate apparent immediate hazards to the
subject.
ensure prompt reporting to the IRB of any unanticipated problems involving
risks to subjects or others or any serious or continuing noncompliance with
this policy or the requirements or determinations of the IRB; and any
suspension or termination of IRB approval.
Operations
of the IRB
Schedule meetings
Distribute complete study documentation to all members for review
prior to the meeting
Vote to approve, require modifications in (to
secure approval), or disapprove research activities based on compliance with
IRB policies
Communicate
with investigators to convey the need for additional information, IRB
decisions, and criteria for appeals.
IRB Record
Requirements
Maintain
current list of membership, qualifications, and contact information
Record
minutes of meetings
Communications
to and from the IRB including annual renewal forms
Records
of continuing review
IRB Review Process
The Principal Investigator (PI) must
submit a complete proposal for SHRI IRB review. Once the IRB receives the proposal, a letter will be sent to
confirm receipt of the proposal. This
letter will also inform the PI if any essential components of the proposal are
missing.
The SHRI IRB will review the
proposal. It is the PI’s
responsibility, however, to submit the proposal to other IRBs, such as a
university, health maintenance organization (HMO), hospital, or other federal
agency (e.g., CDC, NIH) IRBs, as necessary.
The IRB Chair will assign the proposal
to a committee member who has the most experience and background in the area of
study. This committee member will
become the Primary Reviewer (PR). Using
a detailed checklist, the PR will review the proposal.
The PR provides the Chair and IRB
committee members with a summary of his or her review. Each IRB committee member receives a copy of
the submitted proposal and the PR’s review two weeks prior to the next
regularly scheduled IRB meeting.
During the IRB meeting, the committee
has an opportunity to discuss the research proposal. The SHRI IRB can vote to:
¨
Approve as is, or Approve with
Recommendations
¨
Approve with Contingencies
¨
Defer
¨
Disapprove.
A letter with the decision is mailed to
the PI. If the proposal is approved as is, or
approved with recommendations, the work may
begin once the IRB receives final letters of approval from all IRBs. If any changes are made to any part of the
protocol, the changes must first be approved by all the IRBs.
If the proposal is approved with
contingencies, the work may NOT begin until
the PI has responded to the contingencies and has made appropriate changes to
the proposal. The revised proposal must
be submitted to the IRB for its review.
The IRB members will review the PI’s responses at the next regularly
scheduled meeting and vote to either approve, approve with further
contingencies, defer, or disapprove.
If the proposal is deferred,
the work may NOT begin until the PI has responded to IRB
requirements. Most deferrals are
missing key requirements. The revised
proposal must be submitted to the IRB for its review. The IRB members will review the PI’s responses at the next
regularly scheduled meeting and vote to either approve, approve with
contingencies, defer, or disapprove.
If the proposal is disapproved the work may not be conducted. Most disapprovals are missing essential
requirements.
Once the SHRI IRB approves a proposal,
approvals will remain in effect for one year.
At each anniversary of the initial approval, the PI must submit a
research status report to the IRB. The
annual reviews are in effect for the duration of the project. Should any changes to the protocol occur
between reviews by the IRB, the PI should contact and notify the IRB Chair as
soon as possible, especially in reference to adverse effects.
At the completion of the project the PI
is required to submit a final report to SHRI IRB. The PI must obtain SHRI and IRB approval before any public
presentation or publication of the data occurs.
Information the
Investigator Provides IRB
Overview:
Procedures for IRB Review
Research
Proposals
A research packet must contain the following items to be considered complete:
A complete application expedites the review
process. Please submit the original protocol plus 10 copies to the SHRI IRB.
See also Appendix A –
Components of a Research Proposal
Appendix B – Detailed Research Protocol
Annual progress reports
Annual
progress reports are usually done at one-year intervals from the date of
initial review. The IRB will send an annual renewal form to the Principal
Investigator. An annual progress report is considered complete when the
investigators provide the following:
A complete progress report expedites the review
process. If you have any questions, please do not hesitate to contact any
individual in the contact lists.
Publications
A manuscript review packet must contain the following items to be considered
complete:
Expedited review procedures
Expedited review
procedures may be judged appropriate for certain kinds of research involving no
more than minimal risk, and for minor changes in approved research.
Research that may be reviewed by the IRB through an expedited review procedure
includes:
1) some or all of the research found by the reviewer to
involve no more than minimal risk,
2) minor changes in previously approved research during the
period (of one year or less) for which approval is authorized.
Under an expedited review procedure, the review may be carried
out by the IRB chairperson or by one or more experienced reviewers designated
by the chairperson from among members of the IRB. In reviewing the research,
the reviewers may exercise all of the authorities of the IRB except that the
reviewers may not disapprove the research. A research activity may be
disapproved only after review in accordance with the non-expedited procedure.
In the case of an expedited review procedure, all members shall be advised of
research proposals which have been approved under this procedure.
Components of a Research
Proposal
The SHRI IRB’s assessment of your
research proposal involves a series of steps:
(1) identifying the risks associated with the research, as distinguished
from the risks the participants would experience even if not participating in
the research; (2) determining that risks will be minimized; (3) identifying the
probable benefits to be derived from the research; (4) determining that risks
are reasonable in relation to the benefits to the participants, if any, and the
importance of the knowledge to be gained; (5) ensuring that potential
participants will be provided with an accurate and fair description of the
risks or discomforts of the anticipated benefits; and (6) determining the
intervals of periodic review.
To ensure that the IRB completes their
review in a timely manner, your proposal must include the following
information, as applicable:
¨
Cover letter with a list of all
investigators and a contact person and telephone number
¨
Detailed protocol of study
design, sampling, analyses, timelines, evaluation, and community involvement
¨
Informed consent and assent forms
¨
Other attachments, such as a copy
of scripts or survey that will be used, materials that will be distributed,
etc.
If your proposal is missing any
required items, review of your proposal will be delayed.
Detailed Research Protocol
Your research
protocol should discuss in detail how you plan to carry out the research, how
you will analyze the data that you collect, and what you plan to do with the
results. The following are points that
you should address in your protocol.
Introduction
and Background
¨
Provide
relevant research background and explain why this activity is necessary or
important.
¨
Describe
the potential impact of the proposed research.
Study
Design
¨
Provide a complete description of
the study design, sequence, and timing of all study procedures that will be
performed. Provide this information for
pilot, screening, intervention, and follow-up phases. Include all materials that will be used in the procedure, such as
surveys, scripts, questionnaires, etc.
Attach flow sheets if they will help the reader understand the
procedures.
¨
Describe how study procedures
differ from standard care or procedures (e.g., medical, psychological,
educational, etc.).
¨
If any deception or withholding
of complete information is required, explain why this is necessary and attach a
debriefing statement.
¨
Describe where the study will
take place
¨
A letter of approval and
cooperation from each participating site is needed. For example, if the study will be conducted in the local school
system, an approval letter from the School Board and Superintendent are
necessary.
Participants
¨
Explain how the nature of the
research requires or justifies using the participant population.
¨
Provide the approximate number
and ages for the control and experimental groups.
¨
Describe the gender and minority
representation of the participant population.
¨
Describe the criteria for
selection for each participant group.
¨
Describe the exclusion criteria
exclusion for each participant group.
¨
Describe the source for
participants and attach letters of cooperation from agencies, institutions, or
others involved in the recruitment.
¨
Explain who will approach the
participants and how the participants will be approached. Explain what steps you will take to avoid
coercion and protect privacy. Submit
advertisements, flyers, contact letters, and phone contact protocols.
¨
Explain if participants will
receive payments, services without charge, or extra course credit.
¨
Explain if participants will be
charged for any study procedures.
Risks
and Benefits
¨
Describe the nature and amount of
risk of injury, stress, discomfort, invasion of privacy, and other side effects
from all study procedures, drugs, and devices.
Describe the amount of risk the community may be subjected to.
¨
Describe how due care will be
used to minimize risks and maximize benefits.
¨
Describe the provisions for a
continuing reassessment of the balance between risks and benefits.
¨
Describe the data and safety
monitoring committee, if any.
¨
Describe the expected benefits
for individual participants, the community, and society.
Adverse
Effects
¨
Describe how adverse effects will
be handled.
¨
Discuss if facilities and
equipment are adequate to handle possible adverse effects.
¨
Explain who will be financially
responsible for treatment of physical injuries resulting from study procedures
(e.g., study sponsor, subject, organization compensation plan, etc.).
Confidentiality
of Research Data
¨
Explain if data will be anonymous
(no possible link to identifiers).
¨
Explain if identifiable data will
be coded and if the key to the code will be kept separate from the data.
¨
Explain if any other agency or
individual will have access to identifiable data.
¨
Explain how data will be
protected (e.g., computer with restricted access, locked file, etc.).
Consent
Forms and Assent Forms
¨
If the consent form is written,
submit copies of all consent and assent forms for each participant group. If an oral consent or assent script will be
used, submit written scripts for each group.
¨
If you will not use a consent
form or script, submit written justification of waiver of consent.
Drugs,
Substances, and Devices
¨
List all non-investigational
drugs or other substances that will be used during the research. Include the name, source, dose, and method
of administration.
¨
List all investigational drugs or
substances to be used in the study.
Include the name, source, dose, method of administration, IND number,
and phase of testing. (INDs must be
registered with the appropriate institutional pharmacy.) Provide a concise summary of drug
information prepared by the investigator, including available toxicity data,
reports of animal studies, description of studies done in humans, and drug
protocol.
¨
List all investigational devices
to be used. Provide the name, source,
description of purpose, method, and Food and Drug Administration IDE
number. If no IDE is available, explain
why the device qualifies as a non-significant risk. Attach a copy of the protocol, descriptions of studies in humans
and animals, and drawings or photographs of the device.
Additional
Information
¨
Describe how materials with
potential radiation risk will be used (e.g., X-rays and radioisotopes).
¨
If you will use materials with
potential radiation risk, describe the status of annual review by the Radiation
Safety Committee. If the annual review
has been approved, attach a copy of the approval.
¨
Describe the medical, academic,
or other personal records that will be used.
¨
Describe the type of audio-visual
recordings, tape recordings, or photographs that will be made.
¨ Explain if the Scientific Instrument Division will test all instruments. If not, describe the safety testing procedures.
Informed
Consent
Informed
consent is one of the primary ethical requirements underpinning research with
human participants; it reflects the basic principle of respect for people. It is too often forgotten that informed
consent is an ongoing process, not a piece of paper or discrete moment of
time. Informed consent ensures that
prospective participants will understand the nature of the research and can
knowledgably and voluntarily decide whether or not to participate. This protects both the participant,
whose autonomy is respected, and the investigator, who otherwise faces legal
hazards.
The
Nuremburg Code, developed by the International Military Tribunal that
tried Nazi physicians for the “experiments” they performed on unconsenting
inmates of concentration camps, was the first widely recognized document to
deal explicitly with the issue of informed consent and experimentation on human
participants. The first principle of
the code states:
The
voluntary consent of the human subject is absolutely essential. This means that the person involved should
have legal capacity to give consent; should be so situated as to be able to
exercise free power of choice without the intervention of any element of force,
fraud, deceit, duress, over-reaching, or other ulterior form of constraint or
coercion; and should have sufficient knowledge and comprehension of the
elements of the subject matter involved as to enable him to make an
understanding and enlightened decision.
This latter element requires that before the acceptance of an
affirmative decision by the experimental subject, there should be made known to
him the nature, duration, and purpose of the experiment; the method and means
by which it is to be conducted; all inconveniences and hazards reasonably to be
expected; and the effects upon his health or person which may possibly come
from his participation in the experiment.
All
subsequent codes and regulations, insofar as they pertain to competent, adult
participants, follow these principles closely.
Federal
regulations require that certain
information must be provided to each participant:
¨
A statement that the study
involves research, an explanation of the purposes of the research and the
expected duration of participation, a description of the procedures to be
followed, and identification of any procedures which are experimental.
¨
A description of any reasonably
foreseeable risks or discomforts to the participants.
¨
A description of any benefits to
the participant or to others which may reasonably be expected from the
research.
¨
A disclosure of appropriate
alternative procedures or courses of treatment, if any, that might be
advantageous to the participant.
¨
A statement describing the
extent, if any, to which confidentiality of records identifying the participant
will be maintained.
¨
For research involving more than
minimal risk, an explanation as to whether any compensation and an explanation
as to whether any medical treatments are available if injury occurs and, if so,
what they consist of, or where further information may be obtained.
¨
An explanation of whom to contact
for answers to pertinent questions about the research and research
participants’ rights, and whom to contact in the event of a research-related
injury to the participant.
¨
A statement that participation is
voluntary, refusal to participate will involve no penalty or loss of benefits
to which the participant is otherwise entitled, and the participant may
discontinue participation at any time without penalty or loss of benefits to
which the participant is otherwise entitled.
The
regulations further provide that the following additional information be
provided to participants, where appropriate:
¨
A statement that the particular
treatment or procedure may involve risks to the participant (or to the embryo
or fetus, if the participant is or may become pregnant) that are currently
unforeseeable.
¨
Anticipated circumstances under
which the participant’s participation may be terminated by the investigator
without the participant’s consent.
¨
Any additional costs to the
participant that may result from participation in the research.
¨
The consequences of a
participant’s decision to withdraw from the research and procedures for orderly
termination of participation by the participant. If your study offers compensation for participation, specify the
effects of termination of participation on that compensation. (The compensation should be prorated to
reflect the duration of participation rather than an “all or nothing” so that
it appears fair and non-coercive).
¨
A statement that significant new
findings developed during the course of the research that may relate to the
participant’s willingness to continue.
¨
The approximate number of
participants involved in the study.
Investigators may
seek consent only under circumstances that provide the prospective participant
or his or her representative sufficient opportunity to consider whether or not
to participate, and that minimize the possibility of coercion or undue
influence. Furthermore, the information
must be written in language that is understandable to the participant or
representative. The consent process
may not involve the use of exculpatory language through which the participant
or representative is made to waive or appear to waive any of the participant’s
legal rights, or releases or appears to release the investigator, sponsor,
institution, or agents from liability for negligence.
In
your research protocol, you will need to explain the process of
administering consent. The protocol
should address the following questions:
¨
Is consent obtained in a
reasonably quiet, unhurried setting?
¨
Is there a knowledgeable person
present who can answer questions in a clear manner, using layman terms?
¨
Will this knowledgeable
individual assess the participant’s comprehension?
¨
Have you considered the
availability of translators for those who may only speak their native
language? Similarly, if you may be
including participant who are illiterate, deaf, blind, etc., have you
accommodated their needs?
¨
Do you plan to provide a copy of
the consent form to each participant ?
¨
If children (under age 18) are
involved in your study, do you have a parental consent form? If the study involves minimal risk, then
consent of one parent is adequate; if it involves more than minimal risk, then
you must obtain permission of both parents.
¨
If the child is old enough to
make at least some decisions themselves (usually at least 5 or 6 years of age,
but this is specific to their culture), have you set up a form and process for
their assent?
¨
Who will explain the research to
the potential participants? Should
someone in addition to or other than the investigator be present?
¨
Should participants be reeducated
and their consent required periodically?
¨
If a waiver of some or all of the
consent requirements is requested, does the importance of the research justify
such a waiver? Is more than minimal
risk involved? Can the research design
be modified to eliminate the need for deception or incomplete disclosure? Will participants be given more information
after completing their participation?
Would the information to be withheld be something prospective
participants might reasonably want to know in making their decision about
participation?
In
addition to a detailed discussion of the components of the consent and assent
forms and the administration process, you will need to include labeled copies
of each form specifying its type (e.g., parental consent, child assent, regular
consent), participant (e.g., community focus group members, adult vaccine
recipients), and situation where it will be used (e.g., for pretest of
screening instrument, administration of a provider
questionnaire, etc.).
Appendix D
Sample Informed
Consent
Human
BioAcousticsSM
REQUEST, PRIVATE
LICENSE,
INFORMED CONSENT AND
RELEASE
Participant: Date:
Address: Phone:
-----------------------------------------------------------------------------------------------------------------------------
For good
and valuable consideration, the undersigned agree and certify:
First: Constitutional Request
1. The undersigned individual hereby
requests (1) the evaluation of the current energetic, wellness and/or
nutritional state of the undersigned and (2) advice on, and use of, diet,
supplements and/or energetic means, to help the undersigned achieve
and maintain a healthy status, through Human BioAcoustics research vocal
profiling evaluation.
2. The undersigned agrees not to act on
such advice until the undersigned has had an opportunity for an examination by
a licensed physician chosen by the undersigned, and received the evaluation and
advice of such physician.
3. The undersigned makes the above
requests as an exercise of natural right, within the Right of Privacy reserved
by the people under the Constitution of the United States, Ninth Amendment.
4. The
Research Practitioner and agents do not diagnose or prescribe for medical or
psychological conditions nor claim to prevent, treat, mitigate or cure such
conditions. They do not provide diagnosis, care, treatment or
rehabilitation of individuals, nor apply medical, mental health or human
development principles, but rather provide Human BioAcoustic modalities that
may benefit, as permitted under AMA Code 3.04.
Second: Private License
1. The undersigned does hereby privately License the Practitioner, granting same
authority to assist the undersigned in any and all ways to which the
undersigned gives consent. This License
authorizes the services stated in the Constitutional Request, First, above.
Third: Informed Consent and Release
1. The undersigned understands that the
Practitioner and any organization through which the Practitioner conducts
research evaluations only, as ministration for religious, charitable,
scientific research and educational purposes.
The organization(s) and Practitioner(s) do not diagnose,
prescribe for, or treat disease conditions; nor do they claim to prevent,
mitigate or cure disease conditions.
Persons who suspect medical conditions
are advised to seek an appropriate health care professional. Our research may support wellness and
healing, and may support treatment, but is not a treatment of disease by
itself. It is no substitute for a
licensed physician’s diagnosis and treatment.
If the undersigned has been diagnosed by a licensed physician, the
undersigned will disclose this information to the Practitioner.
2. The undersigned does hereby give Informed Consent for Human
BioAcoustic, spiritual, energetic and/or nutritional consulting, as well as
such spiritual, bio-energetic and/or nutritional work as may be conducted by
the Practitioner. The organization and
Practitioner make no medical claims, nor assume any responsibility for any
claims. In no way do they claim that
any energy or vocal analysis equipment or nutritional services should or can be
used to treat any disease condition. The undersigned further understands that any nutritional
substances recommended may be purchased from any supplier. The undersigned has studied the
alternatives and personally chose the work that is to be done.
3. The organization and Practitioners
do not make any representations, promises or guarantees. The recommendations and modalities used are
not intended to, and will not, prevent, mitigate, treat or cure any disease
condition, including, but not limited to, cancer and immune deficiency
diseases.
4. The undersigned does hereby accept full
responsibility for the use of these procedures and advice, releasing, indemnifying and holding the organization and
Practitioners harmless from all
claims arising from participation in these procedures. The undersigned acknowledges that the
Practitioner does not diagnose, treat or claim to prevent, mitigate or cure
human disease. The undersigned agrees
that the undersigned will not bring a complaint or lawsuit against the organization
or Practitioner for any reason, including, but not limited to, the grounds that
these recommendations and modalities are experimental, or are not approved,
accepted or acknowledged to be effective.
Human
BioAcoustics is a research modality.
5. The undersigned does hereby give the organization and
Practitioners permission to use the information gathered during these
procedures, with personal identification removed (anonymous data), for
research and educational purposes.
Dated:
_______________________, 200___.
Research Practitioner Signature Client Signature
Client
Address:
Consent form ã
2005 Ralph Fucetola JD
References
http://www.npaihb.org/epi/irb.html#guidelines
http://www.nihtraining.com/ohsrsite/guidelines/45cfr46.html
http://ohsr.od.nih.gov/IRBCBT/intro.html
http://ninr.cm.net/4200-01.htm
http://www.eh.doe.gov/ohre/roadmap/achre/chap14_2.html
http://www.nihtraining.com/ohsrsite/guidelines/45cfr46.html
http://humansubjects.stanford.edu/nonmedical/IsitHS.html
http://humansubjects.stanford.edu/nonmedical/submission.html
http://www.stanford.edu/dept/DoR/hs/
http://www.fda.gov/oc/ohrt/irbs/faqs.html#IRBOrg
http://ohsr.od.nih.gov/irb/irb.html
http://ohsr.od.nih.gov/irb/OrientationGudelines_Final.pdf
http://www.fda.gov/oc/ohrt/irbs/faqs.html#IRBOrg
Back to SHRI homepage - www.soundhealthresearch.org